Athira Pharma 8-K: Operations, Officer Changes Reported Jan 4

TL;DR

**Athira Pharma filed an 8-K on Jan 8, reporting operational and officer changes from Jan 4, signaling potential shifts.**

AI Summary

Athira Pharma, Inc. filed an 8-K on January 8, 2024, reporting events that occurred on January 4, 2024. This filing indicates that the company is updating its public record regarding its financial condition and changes in officers or directors, as well as compensatory arrangements. For investors, this matters because it signals potential operational or leadership shifts that could impact the company's strategic direction and future performance, which are crucial for evaluating the stock ATHA.

Why It Matters

This filing signals potential changes in Athira Pharma's leadership or financial health, which could influence its strategic direction and stock performance. Investors should monitor subsequent filings for details on these changes.

Risk Assessment

Risk Level: medium — The filing indicates changes in operations and officers, which can introduce uncertainty regarding future company direction and stability.

Analyst Insight

A smart investor would monitor Athira Pharma's subsequent filings and news releases for specific details on the reported operational results and any changes in executive leadership or compensation, as these could significantly impact future stock performance.

Key Numbers

• 001-39503 — Commission File Number (identifies Athira Pharma's registration with the SEC)
• 13 — Public Document Count (number of documents included in the filing)

Key Players & Entities

• Athira Pharma, Inc. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of the earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• 001-39503 (dollar_amount) — Commission File Number
• Atha (company) — trading symbol for Common Stock

Forward-Looking Statements

• Further details regarding the 'Departure of Directors or Certain Officers' will be disclosed in subsequent filings or press releases. (Athira Pharma, Inc.) — medium confidence, target: Q1 2024
• The 'Results of Operations and Financial Condition' mentioned will likely be elaborated upon in the upcoming quarterly earnings report. (Athira Pharma, Inc.) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ATHA The Nasdaq
• $147.4 million — lents and investments, of approximately $147.4 million. The preliminary and unaudited estimate
• $465,000 — e to receive base salary at a rate of US$465,000 per year, remain eligible to participat
• $5,200 — tinue to receive a monthly stipend of US$5,200 to defray costs associated with his man
• $15,200 — ius-consult GmbH (i) a monthly fee of US$15,200 for up to 20 hours of service per month
• $500 — 20 hours of service per month and (ii) $500 per hour of service in excess of 20 hou

Filing Documents

• atha-20240104.htm (8-K) — 56KB
• atha-ex10_1.htm (EX-10.1) — 196KB
• atha-ex99_1.htm (EX-99.1) — 38KB
• img247042425_0.jpg (GRAPHIC) — 18KB
• 0000950170-24-002686.txt ( ) — 477KB
• atha-20240104.xsd (EX-101.SCH) — 27KB
• atha-20240104_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Athira Pharma, Inc. (the “Company”) announced certain information relating to the Company’s financial condition as of December 31, 2023, including its preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and investments, of approximately $147.4 million. The preliminary and unaudited estimate of cash resources is based on management’s initial analysis of operations for the quarter and year ended December 31, 2023, and is subject to further internal review and audit by the Company’s external auditors. A copy of this press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K under Item 2.02 and the press release attached hereto as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 4, 2024, the compensation committee (the “Compensation Committee”) of the board of directors (the “Board”) of Athira Pharma, Inc. (the “Company”) approved an Executive Transition Agreement (“Transition Agreement”) with Dr. Hans Moebius, the Company’s Chief Medical Officer (“CMO”), which Transition Agreement was entered into effective as of January 5, 2024, pursuant to which Dr. Moebius voluntarily resigned his position as CMO effective January 5, 2024, and will continue employm

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are identified by such words as “believe,” “expect,” “anticipate” and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company’s plans, projections, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the Company’s preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and investments. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These statements, like all statements in this report, speak only as of their date. Furthermore, the Company is in the process of finalizing its financial results for the fourth quarter and fiscal year ended December 31, 2023, and therefore the Company’s finalized and audited results and final analysis of those results are not yet available. The preliminary expectations regarding year-end cash, cash equivalents, and investments are the responsibility of management, are subject to management’s review and actual results could differ from management’s expectations. The actual results are also subject to audit by the Company’s independent registered public accounting firm and no assurance is given by the Company’s independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of and for the year ended December 31, 2023, based on the foregoing estimates.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Executive Transition Agreement dated January 5, 2024 99.1 Athira Pharma, Inc. press release dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Athira Pharma, Inc. Date: January 8, 2024 By: /s/ Mark Litton Mark Litton President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR